CD52调控系统性硬化症患者单核细胞黏附与I型干扰素信号
本研究通过RNA测序分析系统性硬化症(SSc)患者CD14+单核细胞转录组,发现黏附与I型干扰素相关基因上调,CD52表达降低而CD11b/CD18升高,且CD52变化与疾病亚型、免疫抑制治疗及自身抗体谱相关。功能实验表明CD52过表达降低单核细胞黏附,而敲低或抗体阻断(阿仑单抗)增加黏附并增强I型干扰素反应。结论提示CD52下调是SSc发病新机制,靶向IFN-HDAC-CD52轴可能为早期SSc治疗选项。
要点
- SSc患者单核细胞CD52表达降低,CD11b/CD18升高,黏附增强。
- CD52过表达减少单核细胞黏附,敲低或阿仑单抗阻断则增强黏附与I型干扰素反应。
- IL-4/IL-13经STAT6上调CD52,LPS及IFN-α/β/γ经JAK1和HDAC IIa下调CD52。
核心结论
- CD14+单核细胞中抗黏附抗原CD52的下调是SSc发病的新机制,靶向IFN-HDAC-CD52轴可能为早期SSc提供新治疗选择。
研究设计与样本
- 研究分析局限型皮肤型SSc(lcSSc)、弥漫型皮肤型SSc(dcSSc)患者及健康对照的循环CD14+单核细胞转录组,并用流式细胞术检测全血CD52、CD11b/integrin αΜ和CD18/integrin β2水平。
- 通过过表达、敲低和抗体阻断CD52,结合基因与蛋白表达检测及功能实验评估CD52对单核细胞黏附的影响。
主要发现
- 通路富集分析显示SSc患者单核细胞中黏附与I型干扰素相关基因增加,CD11b/CD18表达上调、CD52表达降低,对ICAM-1和内皮细胞黏附增强。
- CD52表达变化与SSc亚型、免疫抑制治疗、自身抗体谱及单核细胞黏附特性一致。
- CD52过表达降低CD18水平和单核细胞黏附,而CD52敲低增加单核细胞黏附。
- 在健康对照血样中使用人源化抗CD52单抗阿仑单抗可增加单核细胞黏附、CD11b/CD18表达并增强I型干扰素反应。
- IL-4/IL-13经STAT6通路上调单核细胞CD52表达,而脂多糖及IFN-α、β、γ经JAK1和组蛋白去乙酰化酶IIa(HDAC IIa)依赖方式下调CD52。
临床怎么用
- SSc患者单核细胞CD52低表达与黏附增强相关,监测CD52及CD11b/CD18可能有助于评估单核细胞活化状态。
- 靶向IFN-HDAC-CD52轴可能成为早期SSc的潜在治疗策略,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is characterized by dysregulation of type I interferon (IFN) signaling. CD52 is known for its immunosuppressive functions in T cells. This study was undertaken to investigate the role of CD52 in monocyte adhesion and type I IFN signaling in patients with SSc. METHODS: Transcriptome profiles of circulating CD14+ monocytes from patients with limited cutaneous SSc (lcSSc), patients with diffuse cutaneous SSc (dcSSs), and healthy controls were analyzed by RNA sequencing. Levels of CD52, CD11b/integrin αΜ, and CD18/integrin β2 in whole blood were assessed by flow cytometry. CD52 expression was analyzed in relation to disease phenotype (early, lcSSc, dcSSc) and autoantibody profiles. The impact of overexpression, knockdown, and antibody blocking of CD52 was analyzed by gene and protein expression assays and functional assays. RESULTS: Pathway enrichment analysis indicated an increase in adhesion- and type I IFN-related genes in monocytes from SSc patients. These cells displayed up-regulated expression of CD11b/CD18, reduced expression of CD52, and enhanced adhesion to intercellular adhesion molecule 1 and endothelial cells. Changes in CD52 expression were consistent with the SSc subtypes, as well as with immunosuppressive treatments, autoantibody profiles, and monocyte adhesion properties in patients with SSc. Overexpression of CD52 led to decreased levels of CD18 and monocyte adhesion, while knockdown of CD52 increased monocyte adhesion. Experiments with the humanized anti-CD52 monoclonal antibody alemtuzumab in blood samples from healthy controls increased monocyte adhesion and CD11b/CD18 expression, and enhanced type I IFN responses. Monocytic CD52 expression was up-regulated by interleukin-4 (IL-4)/IL-13 via the STAT6 pathway, and was down-regulated by lipopolysaccharide and IFNs α, β, and γ in a JAK1 and histone deacetylase IIa (HDAC IIa)-dependent manner. CONCLUSION: Down-regulation of the antiadhesion CD52 antigen in CD14+ monocytes represents a novel mechanism in the pathogenesis of SSc. Targeting of the IFN-HDAC-CD52 axis in monocytes might represent a new therapeutic option for patients with early SSc.
引用
- Rudnik M, Rolski F, Jordan S, et al. Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. Arthritis Rheumatol. 2021. PMID: 33760395. doi:10.1002/art.41737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。